Last reviewed · How we verify
Empirical antimicrobial treatment discontinuation
At a glance
| Generic name | Empirical antimicrobial treatment discontinuation |
|---|---|
| Also known as | Clinical rules for finalization of antimicrobial therapy |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever (NA)
- Presepsin to Safely Reduce Antibiotics in Preterm Infants (NA)
- Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
- Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia (NA)
- Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia (PHASE4)
- Trial of MRSA Polymerase Chain Reaction for Pneumonia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: